Skip to main content
SpringerLink
Log in

Why is Acinetobacter baumannii a problem for critically ill patients?

  • What's New in Intensive Care
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474

    Article  CAS  PubMed  Google Scholar 

  2. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C (2003) Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31:2742–2751

    Article  PubMed  Google Scholar 

  3. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D (2003) Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 115:529–535

    Article  PubMed  Google Scholar 

  4. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH (2011) Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 39:46–51

    Article  CAS  PubMed  Google Scholar 

  5. Zhang D, Micek ST, Kollef MH (2015) Time to appropriate antibiotic therapy is an independent determinant of postinfection ICU and hospital lengths of stay in patients with sepsis. Crit Care Med 43:2133–2140

    Article  CAS  PubMed  Google Scholar 

  6. Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernández-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Márquez-Vácaro JA (2014) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40:32–40

    Article  CAS  PubMed  Google Scholar 

  7. Zilberberg MD, Kollef MH, Shorr AF (2015) Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003–2012: a survey study. J Hosp Med. doi:10.1002/jhm.2477

  8. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, EPIC II Group of Investigators (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329

    Article  CAS  PubMed  Google Scholar 

  9. Shorr AF, Zilberberg MD, Micek ST, Kollef MH (2014) Predictors of hospital mortality among septic ICU patients with Acinetobacter spp. bacteremia: a cohort study. BMC Infect Dis 14:572

    Article  PubMed Central  PubMed  Google Scholar 

  10. Chung YK, Kim JS, Lee SS, Lee JA, Kim HS, Shin KS, Park EY, Kang BS, Lee HJ, Kang HJ (2015) Effect of daily chlorhexidine bathing on acquisition of carbapenem-resistant Acinetobacter baumannii (CRAB) in the medical intensive care unit with CRAB endemicity. Am J Infect Control. doi:10.1016/j.ajic.2015.07.001

  11. Apisarnthanarak A, Pinitchai U, Thongphubeth K, Yuekyen C, Warren DK, Fraser VJ, Thammasat University Pandrug-Resistant Acinetobacter baumannii Control Group (2008) A multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study. Clin Infect Dis 47:760–767

    Article  PubMed  Google Scholar 

  12. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, Alp E, Altay FA, Altin N, Arslan F, Aslan T, Bekiroglu N, Cesur S, Celik AD, Dogan M, Durdu B, Duygu F, Engin A, Engin DO, Gonen I, Guclu E, Guven T, Hatipoglu CA, Hosoglu S, Karahocagil MK, Kilic AU, Ormen B, Ozdemir D, Ozer S, Oztoprak N, Sezak N, Turhan V, Turker N, Yilmaz H (2014) Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 33:1311–1322

    Article  CAS  PubMed  Google Scholar 

  13. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R (2013) Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 7:349–358

    Article  Google Scholar 

  14. Bassetti M, Righi E (2015) New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Curr Opin Crit Care 21:402–411

    Article  PubMed  Google Scholar 

  15. Yamamoto N, Hamaguchi S, Akeda Y, Santanirand P, Kerdsin A, Seki M, Ishii Y, Paveenkittiporn W, Bonomo RA, Oishi K, Malathum K, Tomono K (2015) Clinical specimen-direct LAMP: a useful tool for the surveillance of blaOXA-23-positive carbapenem-resistant Acinetobacter baumannii. PLoS One 10:e0133204

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, 4523 Clayton Avenue, Campus Box 8052, St. Louis, MO, USA

    Marin H. Kollef

  2. Division of Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York, NY, USA

    Michael S. Niederman

Authors
  1. Marin H. Kollef
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael S. Niederman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marin H. Kollef.

Ethics declarations

Conflicts of interest

Dr. Kollef’s effort was supported by the Barnes-Jewish Hospital Foundation. There are no other conflicts of interest to report.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kollef, M.H., Niederman, M.S. Why is Acinetobacter baumannii a problem for critically ill patients?. Intensive Care Med 41, 2170–2172 (2015). https://doi.org/10.1007/s00134-015-4096-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-015-4096-3

Keywords

Search

Navigation